JP2020523037A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020523037A5 JP2020523037A5 JP2020518110A JP2020518110A JP2020523037A5 JP 2020523037 A5 JP2020523037 A5 JP 2020523037A5 JP 2020518110 A JP2020518110 A JP 2020518110A JP 2020518110 A JP2020518110 A JP 2020518110A JP 2020523037 A5 JP2020523037 A5 JP 2020523037A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- mouse
- human
- cell
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims description 419
- 108090000623 proteins and genes Proteins 0.000 claims description 120
- 210000000130 stem cell Anatomy 0.000 claims description 102
- 108700019146 Transgenes Proteins 0.000 claims description 90
- 102000004169 proteins and genes Human genes 0.000 claims description 60
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 53
- 230000001939 inductive effect Effects 0.000 claims description 52
- 230000014509 gene expression Effects 0.000 claims description 48
- 239000003814 drug Substances 0.000 claims description 44
- 229940124597 therapeutic agent Drugs 0.000 claims description 42
- 101100494961 Mus musculus Ccl21b gene Proteins 0.000 claims description 39
- 241000700605 Viruses Species 0.000 claims description 39
- 101000638161 Homo sapiens Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 claims description 38
- 201000010099 disease Diseases 0.000 claims description 38
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 38
- 102100028967 HLA class I histocompatibility antigen, alpha chain G Human genes 0.000 claims description 37
- 108010024164 HLA-G Antigens Proteins 0.000 claims description 36
- 239000012190 activator Substances 0.000 claims description 35
- 239000000411 inducer Substances 0.000 claims description 34
- -1 hydroxychloroquin Chemical compound 0.000 claims description 32
- 102000008096 B7-H1 Antigen Human genes 0.000 claims description 29
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 29
- 102100025517 Serpin B9 Human genes 0.000 claims description 29
- 230000000735 allogeneic effect Effects 0.000 claims description 28
- 238000012239 gene modification Methods 0.000 claims description 28
- 230000035755 proliferation Effects 0.000 claims description 24
- 239000003550 marker Substances 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 23
- 241000701022 Cytomegalovirus Species 0.000 claims description 20
- 206010028980 Neoplasm Diseases 0.000 claims description 20
- 230000002401 inhibitory effect Effects 0.000 claims description 19
- 239000000556 agonist Substances 0.000 claims description 17
- 210000001519 tissue Anatomy 0.000 claims description 17
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 16
- 229940088597 hormone Drugs 0.000 claims description 16
- 239000005556 hormone Substances 0.000 claims description 16
- 210000000265 leukocyte Anatomy 0.000 claims description 16
- 210000001778 pluripotent stem cell Anatomy 0.000 claims description 16
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 15
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 15
- 239000000126 substance Substances 0.000 claims description 15
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 15
- 239000003112 inhibitor Substances 0.000 claims description 14
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 14
- 230000004663 cell proliferation Effects 0.000 claims description 13
- 230000032823 cell division Effects 0.000 claims description 12
- 230000005017 genetic modification Effects 0.000 claims description 12
- 235000013617 genetically modified food Nutrition 0.000 claims description 12
- 230000001506 immunosuppresive effect Effects 0.000 claims description 12
- 210000004379 membrane Anatomy 0.000 claims description 12
- 239000012528 membrane Substances 0.000 claims description 12
- 208000024827 Alzheimer disease Diseases 0.000 claims description 11
- 102000004190 Enzymes Human genes 0.000 claims description 11
- 108090000790 Enzymes Proteins 0.000 claims description 11
- 208000023105 Huntington disease Diseases 0.000 claims description 11
- 208000018737 Parkinson disease Diseases 0.000 claims description 11
- 201000011510 cancer Diseases 0.000 claims description 11
- 150000001875 compounds Chemical class 0.000 claims description 11
- 230000007812 deficiency Effects 0.000 claims description 11
- 208000016097 disease of metabolism Diseases 0.000 claims description 11
- 208000030159 metabolic disease Diseases 0.000 claims description 11
- 201000006417 multiple sclerosis Diseases 0.000 claims description 11
- 208000010125 myocardial infarction Diseases 0.000 claims description 11
- 208000020431 spinal cord injury Diseases 0.000 claims description 11
- 101100321817 Human parvovirus B19 (strain HV) 7.5K gene Proteins 0.000 claims description 10
- 206010062016 Immunosuppression Diseases 0.000 claims description 10
- 241000713333 Mouse mammary tumor virus Species 0.000 claims description 10
- 241001494479 Pecora Species 0.000 claims description 10
- 241000700618 Vaccinia virus Species 0.000 claims description 10
- 210000004504 adult stem cell Anatomy 0.000 claims description 10
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 claims description 10
- 230000012010 growth Effects 0.000 claims description 10
- 210000002510 keratinocyte Anatomy 0.000 claims description 10
- 210000004072 lung Anatomy 0.000 claims description 10
- 230000002107 myocardial effect Effects 0.000 claims description 10
- 210000002437 synoviocyte Anatomy 0.000 claims description 10
- 241000701161 unidentified adenovirus Species 0.000 claims description 10
- 108020004414 DNA Proteins 0.000 claims description 9
- 229940123907 Disease modifying antirheumatic drug Drugs 0.000 claims description 9
- 206010039491 Sarcoma Diseases 0.000 claims description 9
- 210000003321 cartilage cell Anatomy 0.000 claims description 9
- 239000002988 disease modifying antirheumatic drug Substances 0.000 claims description 9
- 230000006698 induction Effects 0.000 claims description 9
- 238000002054 transplantation Methods 0.000 claims description 9
- 208000023275 Autoimmune disease Diseases 0.000 claims description 8
- 201000004569 Blindness Diseases 0.000 claims description 8
- 208000019838 Blood disease Diseases 0.000 claims description 8
- 208000031220 Hemophilia Diseases 0.000 claims description 8
- 208000009292 Hemophilia A Diseases 0.000 claims description 8
- 208000032578 Inherited retinal disease Diseases 0.000 claims description 8
- 208000019693 Lung disease Diseases 0.000 claims description 8
- 208000032430 Retinal dystrophy Diseases 0.000 claims description 8
- 208000006011 Stroke Diseases 0.000 claims description 8
- 238000002679 ablation Methods 0.000 claims description 8
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 8
- 206010003246 arthritis Diseases 0.000 claims description 8
- 230000033228 biological regulation Effects 0.000 claims description 8
- 230000007850 degeneration Effects 0.000 claims description 8
- 206010012601 diabetes mellitus Diseases 0.000 claims description 8
- 238000006471 dimerization reaction Methods 0.000 claims description 8
- 201000006321 fundus dystrophy Diseases 0.000 claims description 8
- 208000014951 hematologic disease Diseases 0.000 claims description 8
- 208000018706 hematopoietic system disease Diseases 0.000 claims description 8
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims description 8
- 208000015181 infectious disease Diseases 0.000 claims description 8
- 208000017532 inherited retinal dystrophy Diseases 0.000 claims description 8
- 208000028867 ischemia Diseases 0.000 claims description 8
- 239000003446 ligand Substances 0.000 claims description 8
- 230000007246 mechanism Effects 0.000 claims description 8
- 210000004498 neuroglial cell Anatomy 0.000 claims description 8
- 210000002569 neuron Anatomy 0.000 claims description 8
- 230000002441 reversible effect Effects 0.000 claims description 8
- UPEZCKBFRMILAV-JNEQICEOSA-N Ecdysone Natural products O=C1[C@H]2[C@@](C)([C@@H]3C([C@@]4(O)[C@@](C)([C@H]([C@H]([C@@H](O)CCC(O)(C)C)C)CC4)CC3)=C1)C[C@H](O)[C@H](O)C2 UPEZCKBFRMILAV-JNEQICEOSA-N 0.000 claims description 7
- UPEZCKBFRMILAV-UHFFFAOYSA-N alpha-Ecdysone Natural products C1C(O)C(O)CC2(C)C(CCC3(C(C(C(O)CCC(C)(C)O)C)CCC33O)C)C3=CC(=O)C21 UPEZCKBFRMILAV-UHFFFAOYSA-N 0.000 claims description 7
- UPEZCKBFRMILAV-JMZLNJERSA-N ecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@H]([C@H](O)CCC(C)(C)O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 UPEZCKBFRMILAV-JMZLNJERSA-N 0.000 claims description 7
- 210000002540 macrophage Anatomy 0.000 claims description 7
- 238000011282 treatment Methods 0.000 claims description 7
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 6
- 229930105110 Cyclosporin A Natural products 0.000 claims description 6
- 108010036949 Cyclosporine Proteins 0.000 claims description 6
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 claims description 6
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 6
- 108091000080 Phosphotransferase Proteins 0.000 claims description 6
- 229960002964 adalimumab Drugs 0.000 claims description 6
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims description 6
- 239000002876 beta blocker Substances 0.000 claims description 6
- 229940097320 beta blocking agent Drugs 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 6
- 239000008280 blood Substances 0.000 claims description 6
- 210000001185 bone marrow Anatomy 0.000 claims description 6
- 210000001612 chondrocyte Anatomy 0.000 claims description 6
- 229960001265 ciclosporin Drugs 0.000 claims description 6
- 239000003246 corticosteroid Substances 0.000 claims description 6
- 239000002532 enzyme inhibitor Substances 0.000 claims description 6
- 229940125532 enzyme inhibitor Drugs 0.000 claims description 6
- 229960002963 ganciclovir Drugs 0.000 claims description 6
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 claims description 6
- 210000004602 germ cell Anatomy 0.000 claims description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 6
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 6
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 6
- 239000002777 nucleoside Chemical class 0.000 claims description 6
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 6
- 102000020233 phosphotransferase Human genes 0.000 claims description 6
- 238000010839 reverse transcription Methods 0.000 claims description 6
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 6
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 claims description 6
- 229960001940 sulfasalazine Drugs 0.000 claims description 6
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 claims description 6
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims description 6
- 229940104230 thymidine Drugs 0.000 claims description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 5
- 102000008873 Angiotensin II receptor Human genes 0.000 claims description 5
- 108050000824 Angiotensin II receptor Proteins 0.000 claims description 5
- 102100032857 Cyclin-dependent kinase 1 Human genes 0.000 claims description 5
- 101710106279 Cyclin-dependent kinase 1 Proteins 0.000 claims description 5
- 101150115146 EEF2 gene Proteins 0.000 claims description 5
- 208000009889 Herpes Simplex Diseases 0.000 claims description 5
- 101001098352 Homo sapiens OX-2 membrane glycoprotein Proteins 0.000 claims description 5
- 102100037589 OX-2 membrane glycoprotein Human genes 0.000 claims description 5
- 108091027981 Response element Proteins 0.000 claims description 5
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 5
- 239000004098 Tetracycline Substances 0.000 claims description 5
- 230000004913 activation Effects 0.000 claims description 5
- 210000001789 adipocyte Anatomy 0.000 claims description 5
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 5
- 210000000013 bile duct Anatomy 0.000 claims description 5
- 210000000601 blood cell Anatomy 0.000 claims description 5
- 210000000988 bone and bone Anatomy 0.000 claims description 5
- 210000002449 bone cell Anatomy 0.000 claims description 5
- 210000004556 brain Anatomy 0.000 claims description 5
- 210000001593 brown adipocyte Anatomy 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 5
- 230000002124 endocrine Effects 0.000 claims description 5
- 210000002889 endothelial cell Anatomy 0.000 claims description 5
- 230000003511 endothelial effect Effects 0.000 claims description 5
- 210000002919 epithelial cell Anatomy 0.000 claims description 5
- 210000003999 epithelial cell of bile duct Anatomy 0.000 claims description 5
- 210000002907 exocrine cell Anatomy 0.000 claims description 5
- 210000004700 fetal blood Anatomy 0.000 claims description 5
- 210000002950 fibroblast Anatomy 0.000 claims description 5
- 238000010362 genome editing Methods 0.000 claims description 5
- 210000003780 hair follicle Anatomy 0.000 claims description 5
- 210000002216 heart Anatomy 0.000 claims description 5
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 5
- 210000003494 hepatocyte Anatomy 0.000 claims description 5
- 210000004966 intestinal stem cell Anatomy 0.000 claims description 5
- 210000000936 intestine Anatomy 0.000 claims description 5
- 210000003734 kidney Anatomy 0.000 claims description 5
- 208000032839 leukemia Diseases 0.000 claims description 5
- 210000004523 ligament cell Anatomy 0.000 claims description 5
- 210000004185 liver Anatomy 0.000 claims description 5
- 230000005499 meniscus Effects 0.000 claims description 5
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 5
- 210000003098 myoblast Anatomy 0.000 claims description 5
- 210000000496 pancreas Anatomy 0.000 claims description 5
- 210000000134 pericardial cell Anatomy 0.000 claims description 5
- 210000002826 placenta Anatomy 0.000 claims description 5
- 230000002285 radioactive effect Effects 0.000 claims description 5
- 230000003248 secreting effect Effects 0.000 claims description 5
- 210000003728 serous cell Anatomy 0.000 claims description 5
- 210000002363 skeletal muscle cell Anatomy 0.000 claims description 5
- 210000003491 skin Anatomy 0.000 claims description 5
- 210000000329 smooth muscle myocyte Anatomy 0.000 claims description 5
- 210000001082 somatic cell Anatomy 0.000 claims description 5
- 210000001988 somatic stem cell Anatomy 0.000 claims description 5
- 210000002325 somatostatin-secreting cell Anatomy 0.000 claims description 5
- 210000000278 spinal cord Anatomy 0.000 claims description 5
- 210000000952 spleen Anatomy 0.000 claims description 5
- 210000002784 stomach Anatomy 0.000 claims description 5
- 210000002435 tendon Anatomy 0.000 claims description 5
- 229960002180 tetracycline Drugs 0.000 claims description 5
- 229930101283 tetracycline Natural products 0.000 claims description 5
- 235000019364 tetracycline Nutrition 0.000 claims description 5
- 150000003522 tetracyclines Chemical class 0.000 claims description 5
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- 210000003932 urinary bladder Anatomy 0.000 claims description 5
- 210000000636 white adipocyte Anatomy 0.000 claims description 5
- 229940100389 Sulfonylurea Drugs 0.000 claims description 4
- 239000012620 biological material Substances 0.000 claims description 4
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims description 3
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 claims description 3
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical class COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 claims description 3
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 claims description 3
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 claims description 3
- 239000005541 ACE inhibitor Substances 0.000 claims description 3
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 3
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 claims description 3
- 229940123208 Biguanide Drugs 0.000 claims description 3
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims description 3
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims description 3
- 229940127291 Calcium channel antagonist Drugs 0.000 claims description 3
- 102000013392 Carboxylesterase Human genes 0.000 claims description 3
- 108010051152 Carboxylesterase Proteins 0.000 claims description 3
- 102000011682 Centromere Protein A Human genes 0.000 claims description 3
- 108010076303 Centromere Protein A Proteins 0.000 claims description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 3
- 230000004543 DNA replication Effects 0.000 claims description 3
- 102100033587 DNA topoisomerase 2-alpha Human genes 0.000 claims description 3
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 claims description 3
- 208000027219 Deficiency disease Diseases 0.000 claims description 3
- 241000208011 Digitalis Species 0.000 claims description 3
- 102100031334 Elongation factor 2 Human genes 0.000 claims description 3
- 108010008165 Etanercept Proteins 0.000 claims description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Natural products OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 3
- 108010072051 Glatiramer Acetate Proteins 0.000 claims description 3
- 206010020843 Hyperthermia Diseases 0.000 claims description 3
- 108090001061 Insulin Proteins 0.000 claims description 3
- 102000003996 Interferon-beta Human genes 0.000 claims description 3
- 108090000467 Interferon-beta Proteins 0.000 claims description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 3
- 229940122048 Leucotriene receptor antagonist Drugs 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 3
- 102000010909 Monoamine Oxidase Human genes 0.000 claims description 3
- 108010062431 Monoamine oxidase Proteins 0.000 claims description 3
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims description 3
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims description 3
- 229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 claims description 3
- 108010002687 Survivin Proteins 0.000 claims description 3
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims description 3
- 229940123464 Thiazolidinedione Drugs 0.000 claims description 3
- 239000004012 Tofacitinib Substances 0.000 claims description 3
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 claims description 3
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 claims description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 3
- 229960000548 alemtuzumab Drugs 0.000 claims description 3
- 239000002160 alpha blocker Substances 0.000 claims description 3
- 239000003888 alpha glucosidase inhibitor Substances 0.000 claims description 3
- 229940124308 alpha-adrenoreceptor antagonist Drugs 0.000 claims description 3
- 229940113720 aminosalicylate Drugs 0.000 claims description 3
- 239000002269 analeptic agent Substances 0.000 claims description 3
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims description 3
- 239000003242 anti bacterial agent Substances 0.000 claims description 3
- 230000000844 anti-bacterial effect Effects 0.000 claims description 3
- 230000000843 anti-fungal effect Effects 0.000 claims description 3
- 230000001387 anti-histamine Effects 0.000 claims description 3
- 230000002141 anti-parasite Effects 0.000 claims description 3
- 230000000840 anti-viral effect Effects 0.000 claims description 3
- 229940088710 antibiotic agent Drugs 0.000 claims description 3
- 239000003146 anticoagulant agent Substances 0.000 claims description 3
- 229940127219 anticoagulant drug Drugs 0.000 claims description 3
- 229940121375 antifungal agent Drugs 0.000 claims description 3
- 239000000739 antihistaminic agent Substances 0.000 claims description 3
- 239000003096 antiparasitic agent Chemical class 0.000 claims description 3
- 150000004283 biguanides Chemical class 0.000 claims description 3
- 239000003613 bile acid Substances 0.000 claims description 3
- 239000003124 biologic agent Substances 0.000 claims description 3
- 230000008512 biological response Effects 0.000 claims description 3
- 239000003114 blood coagulation factor Substances 0.000 claims description 3
- 239000000480 calcium channel blocker Substances 0.000 claims description 3
- 229940022399 cancer vaccine Drugs 0.000 claims description 3
- 230000000747 cardiac effect Effects 0.000 claims description 3
- 210000004413 cardiac myocyte Anatomy 0.000 claims description 3
- 239000003543 catechol methyltransferase inhibitor Substances 0.000 claims description 3
- 230000022131 cell cycle Effects 0.000 claims description 3
- 238000002659 cell therapy Methods 0.000 claims description 3
- 230000001906 cholesterol absorption Effects 0.000 claims description 3
- 239000000812 cholinergic antagonist Substances 0.000 claims description 3
- 239000005515 coenzyme Substances 0.000 claims description 3
- 238000000315 cryotherapy Methods 0.000 claims description 3
- 229960004397 cyclophosphamide Drugs 0.000 claims description 3
- 229930182912 cyclosporin Natural products 0.000 claims description 3
- 229960004281 desmopressin Drugs 0.000 claims description 3
- NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 claims description 3
- 238000000502 dialysis Methods 0.000 claims description 3
- 230000037213 diet Effects 0.000 claims description 3
- 235000005911 diet Nutrition 0.000 claims description 3
- LDCRTTXIJACKKU-ONEGZZNKSA-N dimethyl fumarate Chemical compound COC(=O)\C=C\C(=O)OC LDCRTTXIJACKKU-ONEGZZNKSA-N 0.000 claims description 3
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 claims description 3
- 239000002934 diuretic Substances 0.000 claims description 3
- 229940030606 diuretics Drugs 0.000 claims description 3
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims description 3
- 238000002641 enzyme replacement therapy Methods 0.000 claims description 3
- 229960000403 etanercept Drugs 0.000 claims description 3
- 239000001530 fumaric acid Substances 0.000 claims description 3
- 229960003776 glatiramer acetate Drugs 0.000 claims description 3
- 229960001743 golimumab Drugs 0.000 claims description 3
- 230000036031 hyperthermia Effects 0.000 claims description 3
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 3
- 230000001861 immunosuppressant effect Effects 0.000 claims description 3
- 239000003018 immunosuppressive agent Substances 0.000 claims description 3
- 229940125396 insulin Drugs 0.000 claims description 3
- 229960004768 irinotecan Drugs 0.000 claims description 3
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 3
- 229960000681 leflunomide Drugs 0.000 claims description 3
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 claims description 3
- 229960004502 levodopa Drugs 0.000 claims description 3
- 229940127212 long-acting beta 2 agonist Drugs 0.000 claims description 3
- 239000011159 matrix material Substances 0.000 claims description 3
- 229950004994 meglitinide Drugs 0.000 claims description 3
- 230000002503 metabolic effect Effects 0.000 claims description 3
- 229960000485 methotrexate Drugs 0.000 claims description 3
- 229960004584 methylprednisolone Drugs 0.000 claims description 3
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 claims description 3
- 229960001156 mitoxantrone Drugs 0.000 claims description 3
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 3
- 239000003607 modifier Substances 0.000 claims description 3
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 claims description 3
- 229960005027 natalizumab Drugs 0.000 claims description 3
- 229960003512 nicotinic acid Drugs 0.000 claims description 3
- 239000011664 nicotinic acid Substances 0.000 claims description 3
- 235000001968 nicotinic acid Nutrition 0.000 claims description 3
- 210000000056 organ Anatomy 0.000 claims description 3
- 206010033675 panniculitis Diseases 0.000 claims description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 3
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 3
- 230000010412 perfusion Effects 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 210000000608 photoreceptor cell Anatomy 0.000 claims description 3
- 238000000554 physical therapy Methods 0.000 claims description 3
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims description 3
- 229960005205 prednisolone Drugs 0.000 claims description 3
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 239000003755 preservative agent Substances 0.000 claims description 3
- 239000006041 probiotic Substances 0.000 claims description 3
- 230000000529 probiotic effect Effects 0.000 claims description 3
- 235000018291 probiotics Nutrition 0.000 claims description 3
- 230000022558 protein metabolic process Effects 0.000 claims description 3
- 238000001959 radiotherapy Methods 0.000 claims description 3
- 229960003876 ranibizumab Drugs 0.000 claims description 3
- 238000002271 resection Methods 0.000 claims description 3
- 150000004492 retinoid derivatives Chemical class 0.000 claims description 3
- 229960004889 salicylic acid Drugs 0.000 claims description 3
- 238000010254 subcutaneous injection Methods 0.000 claims description 3
- 239000007929 subcutaneous injection Substances 0.000 claims description 3
- 210000004304 subcutaneous tissue Anatomy 0.000 claims description 3
- 238000006467 substitution reaction Methods 0.000 claims description 3
- 229960000331 teriflunomide Drugs 0.000 claims description 3
- UTNUDOFZCWSZMS-YFHOEESVSA-N teriflunomide Chemical compound C\C(O)=C(/C#N)C(=O)NC1=CC=C(C(F)(F)F)C=C1 UTNUDOFZCWSZMS-YFHOEESVSA-N 0.000 claims description 3
- 229960000278 theophylline Drugs 0.000 claims description 3
- 229960003087 tioguanine Drugs 0.000 claims description 3
- 229960001350 tofacitinib Drugs 0.000 claims description 3
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 claims description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 3
- 230000035897 transcription Effects 0.000 claims description 3
- 238000013518 transcription Methods 0.000 claims description 3
- 230000014616 translation Effects 0.000 claims description 3
- 229940124549 vasodilator Drugs 0.000 claims description 3
- 239000003071 vasodilator agent Substances 0.000 claims description 3
- 102000000311 Cytosine Deaminase Human genes 0.000 claims description 2
- 108010080611 Cytosine Deaminase Proteins 0.000 claims description 2
- 108010080379 Fibrin Tissue Adhesive Proteins 0.000 claims description 2
- 238000010322 bone marrow transplantation Methods 0.000 claims description 2
- 230000000368 destabilizing effect Effects 0.000 claims description 2
- 230000002335 preservative effect Effects 0.000 claims description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 claims description 2
- 101000713085 Homo sapiens C-C motif chemokine 21 Proteins 0.000 claims 9
- 101001034314 Homo sapiens Lactadherin Proteins 0.000 claims 9
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims 9
- 101000836075 Homo sapiens Serpin B9 Proteins 0.000 claims 9
- 101100135227 Mus musculus Cd200 gene Proteins 0.000 claims 9
- 101100059528 Mus musculus Cd47 gene Proteins 0.000 claims 9
- 101100076830 Mus musculus Mfge8 gene Proteins 0.000 claims 9
- 101000638240 Mus musculus Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 claims 9
- 102000053535 human FASLG Human genes 0.000 claims 9
- 108700035927 mouse Serpinb9 Proteins 0.000 claims 9
- 101100135226 Homo sapiens CD200 gene Proteins 0.000 claims 8
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims 8
- 102000043711 human CCL21 Human genes 0.000 claims 8
- 102000048776 human CD274 Human genes 0.000 claims 8
- 102000044459 human CD47 Human genes 0.000 claims 8
- 102000051386 human MFGE8 Human genes 0.000 claims 8
- 102000046606 human SERPINB9 Human genes 0.000 claims 8
- 239000002243 precursor Substances 0.000 claims 6
- 241000714474 Rous sarcoma virus Species 0.000 claims 3
- 102100022464 5'-nucleotidase Human genes 0.000 claims 2
- 102100022718 Atypical chemokine receptor 2 Human genes 0.000 claims 2
- 102100029722 Ectonucleoside triphosphate diphosphohydrolase 1 Human genes 0.000 claims 2
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 claims 2
- 101000678892 Homo sapiens Atypical chemokine receptor 2 Proteins 0.000 claims 2
- 101001012447 Homo sapiens Ectonucleoside triphosphate diphosphohydrolase 1 Proteins 0.000 claims 2
- 101001076422 Homo sapiens Interleukin-1 receptor type 2 Proteins 0.000 claims 2
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims 2
- 102100026017 Interleukin-1 receptor type 2 Human genes 0.000 claims 2
- 102000017578 LAG3 Human genes 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 claims 1
- 102000005862 Angiotensin II Human genes 0.000 claims 1
- 101800000733 Angiotensin-2 Proteins 0.000 claims 1
- 102100036846 C-C motif chemokine 21 Human genes 0.000 claims 1
- 102100039104 Dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit DAD1 Human genes 0.000 claims 1
- 229940123611 Genome editing Drugs 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 101000884921 Homo sapiens Dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit DAD1 Proteins 0.000 claims 1
- 241000519695 Ilex integra Species 0.000 claims 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 1
- 102100023915 Insulin Human genes 0.000 claims 1
- 102100039648 Lactadherin Human genes 0.000 claims 1
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims 1
- 241000700584 Simplexvirus Species 0.000 claims 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 229950006323 angiotensin ii Drugs 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 229940107161 cholesterol Drugs 0.000 claims 1
- 229960004419 dimethyl fumarate Drugs 0.000 claims 1
- 229940052760 dopamine agonists Drugs 0.000 claims 1
- 230000002349 favourable effect Effects 0.000 claims 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 1
- 229960000598 infliximab Drugs 0.000 claims 1
- 210000004216 mammary stem cell Anatomy 0.000 claims 1
- 229940014456 mycophenolate Drugs 0.000 claims 1
- 210000001178 neural stem cell Anatomy 0.000 claims 1
- 230000000649 photocoagulation Effects 0.000 claims 1
- 238000002428 photodynamic therapy Methods 0.000 claims 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 claims 1
- 150000001467 thiazolidinediones Chemical class 0.000 claims 1
- 238000000034 method Methods 0.000 description 125
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 58
- 108010039471 Fas Ligand Protein Proteins 0.000 description 29
- 101150084532 CD47 gene Proteins 0.000 description 28
- 101150105660 MFGE8 gene Proteins 0.000 description 28
- 101710156153 Serpin B9 Proteins 0.000 description 28
- 101150059225 Cd200 gene Proteins 0.000 description 24
- 101150030213 Lag3 gene Proteins 0.000 description 11
- 230000001276 controlling effect Effects 0.000 description 11
- 101150037150 DAD1 gene Proteins 0.000 description 8
- 101150117736 Entpd1 gene Proteins 0.000 description 8
- 101100153523 Mus musculus Tnfrsf22 gene Proteins 0.000 description 7
- 210000000481 breast Anatomy 0.000 description 6
- 208000035473 Communicable disease Diseases 0.000 description 5
- 101150079765 Ackr2 gene Proteins 0.000 description 4
- 101150012716 CDK1 gene Proteins 0.000 description 4
- 101150111528 IL1R2 gene Proteins 0.000 description 4
- 229940127218 antiplatelet drug Drugs 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 210000003979 eosinophil Anatomy 0.000 description 4
- 239000007943 implant Substances 0.000 description 4
- 210000005036 nerve Anatomy 0.000 description 4
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 2
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 2
- 101150115284 BIRC5 gene Proteins 0.000 description 2
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 2
- 229940099362 Catechol O methyltransferase inhibitor Drugs 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 2
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- 239000003529 anticholesteremic agent Substances 0.000 description 2
- 229940127226 anticholesterol agent Drugs 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000001461 cytolytic effect Effects 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000000925 erythroid effect Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000001631 haemodialysis Methods 0.000 description 2
- 230000000322 hemodialysis Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000002101 lytic effect Effects 0.000 description 2
- 210000005075 mammary gland Anatomy 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 229960000951 mycophenolic acid Drugs 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 229940127211 short-acting beta 2 agonist Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000588 tumorigenic Toxicity 0.000 description 2
- 230000000381 tumorigenic effect Effects 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 101100395318 Homo sapiens HLA-G gene Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 1
- 229960004413 flucytosine Drugs 0.000 description 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
- 229960004171 hydroxychloroquine Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- UQRORFVVSGFNRO-UTINFBMNSA-N miglustat Chemical compound CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO UQRORFVVSGFNRO-UTINFBMNSA-N 0.000 description 1
- 229960001512 miglustat Drugs 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000000565 sealant Substances 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023197046A JP7724834B2 (ja) | 2017-06-12 | 2023-11-21 | 全身免疫抑制を必要としない同種免疫寛容 |
| JP2025130460A JP2025163187A (ja) | 2017-06-12 | 2025-08-05 | 全身免疫抑制を必要としない同種免疫寛容 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762518151P | 2017-06-12 | 2017-06-12 | |
| US62/518,151 | 2017-06-12 | ||
| US201862666626P | 2018-05-03 | 2018-05-03 | |
| US62/666,626 | 2018-05-03 | ||
| PCT/CA2018/050706 WO2018227286A1 (en) | 2017-06-12 | 2018-06-12 | Allograft tolerance without the need for systemic immune suppression |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023197046A Division JP7724834B2 (ja) | 2017-06-12 | 2023-11-21 | 全身免疫抑制を必要としない同種免疫寛容 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020523037A JP2020523037A (ja) | 2020-08-06 |
| JP2020523037A5 true JP2020523037A5 (enExample) | 2021-08-12 |
| JP7391016B2 JP7391016B2 (ja) | 2023-12-04 |
Family
ID=64658770
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020518110A Active JP7391016B2 (ja) | 2017-06-12 | 2018-06-12 | 全身免疫抑制を必要としない同種免疫寛容 |
| JP2023197046A Active JP7724834B2 (ja) | 2017-06-12 | 2023-11-21 | 全身免疫抑制を必要としない同種免疫寛容 |
| JP2025130460A Pending JP2025163187A (ja) | 2017-06-12 | 2025-08-05 | 全身免疫抑制を必要としない同種免疫寛容 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023197046A Active JP7724834B2 (ja) | 2017-06-12 | 2023-11-21 | 全身免疫抑制を必要としない同種免疫寛容 |
| JP2025130460A Pending JP2025163187A (ja) | 2017-06-12 | 2025-08-05 | 全身免疫抑制を必要としない同種免疫寛容 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US20210161971A1 (enExample) |
| EP (1) | EP3638258A4 (enExample) |
| JP (3) | JP7391016B2 (enExample) |
| KR (2) | KR20250005439A (enExample) |
| CN (2) | CN120041380A (enExample) |
| AU (3) | AU2018285972B2 (enExample) |
| CA (1) | CA3064297A1 (enExample) |
| GB (1) | GB2588249B (enExample) |
| IL (2) | IL270835B2 (enExample) |
| WO (1) | WO2018227286A1 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| CA2935960C (en) | 2014-01-08 | 2023-01-10 | Bart Lipkens | Acoustophoresis device with dual acoustophoretic chamber |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| HK1254190A1 (zh) | 2015-05-08 | 2019-07-12 | President And Fellows Of Harvard College | 通用供体干细胞和相关方法 |
| KR20220066413A (ko) | 2017-12-14 | 2022-05-24 | 프로디자인 소닉스, 인크. | 음향 트랜스듀서 구동기 및 제어기 |
| MX2020007071A (es) | 2018-01-05 | 2020-11-11 | Platelet Biogenesis Inc | Composiciones y metodos para producir megacariocitos. |
| WO2020006539A1 (en) | 2018-06-29 | 2020-01-02 | Platelet Biogenesis, Inc. | Compositions for drug delivery and methods of use thereof |
| US10724052B2 (en) | 2018-09-07 | 2020-07-28 | Crispr Therapeutics Ag | Universal donor cells |
| WO2020118447A1 (en) * | 2018-12-13 | 2020-06-18 | Sinai Health System | Immunomodulatory cells and uses thereof |
| CN113544261B (zh) * | 2019-02-27 | 2024-10-01 | 武田药品工业株式会社 | 用于同种异体疗法的改良的干细胞群 |
| CN110179824A (zh) * | 2019-04-01 | 2019-08-30 | 普米斯生物技术(珠海)有限公司 | 一种通过免疫调控治疗ii型糖尿病的新方法 |
| SG11202112506SA (en) | 2019-05-10 | 2021-12-30 | Univ California | Modified pluripotent cells |
| US11162079B2 (en) | 2019-05-10 | 2021-11-02 | The Regents Of The University Of California | Blood type O Rh-hypo-immunogenic pluripotent cells |
| EP4021934A4 (en) * | 2019-08-30 | 2024-02-14 | The Regents of the University of California | Gene fragment overexpression screening methodologies, and uses thereof |
| AU2020340622A1 (en) | 2019-09-05 | 2022-03-03 | Crispr Therapeutics Ag | Universal donor cells |
| CA3164591A1 (en) | 2020-01-13 | 2021-07-22 | William Dowdle | Modification of blood type antigens |
| WO2021163451A1 (en) * | 2020-02-14 | 2021-08-19 | Asklepios Biopharmaceutical, Inc. | Method of treating gene therapy associated toxicity with antibiotics |
| WO2021197430A1 (en) * | 2020-04-01 | 2021-10-07 | Nanjing Legend Biotech Co., Ltd. | Compositions and methods for reducing graft rejection in allogeneic cell therapy |
| CN115697355A (zh) * | 2020-04-30 | 2023-02-03 | 全国儿童医院研究所 | 用抗TGF-β的NK细胞克服免疫抑制 |
| CN112089847B (zh) * | 2020-08-31 | 2021-05-28 | 高连如 | 一种融合pnv靶向缺血心肌血管的干细胞药物及制备方法 |
| US11591381B2 (en) | 2020-11-30 | 2023-02-28 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
| EP4271798A1 (en) | 2020-12-30 | 2023-11-08 | CRISPR Therapeutics AG | Compositions and methods for differentiating stem cells into nk cells |
| AU2021414405A1 (en) | 2020-12-31 | 2023-08-10 | Crispr Therapeutics Ag | Universal donor cells |
| CN112972681B (zh) * | 2021-01-27 | 2022-06-07 | 西安交通大学 | Mt-nd6作为新靶点在代谢综合征诊断和治疗药物中的应用 |
| CN115124625B (zh) * | 2021-03-24 | 2024-11-26 | 圣安生医股份有限公司 | 免疫调节及抗肿瘤相关纳米抗体、其核酸编码序列及应用 |
| US20230016422A1 (en) * | 2021-06-23 | 2023-01-19 | Crispr Therapeutics Ag | Engineered cells with improved protection from natural killer cell killing |
| WO2023023278A2 (en) * | 2021-08-18 | 2023-02-23 | University Of Utah Research Foundation | Multigene constructs for treatment of age-related macular degeneration and other complement dysregulation-related conditions |
| WO2023098729A1 (en) * | 2021-11-30 | 2023-06-08 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animal with human or chimeric genes |
| KR102803344B1 (ko) * | 2022-01-19 | 2025-05-07 | 고려대학교 산학협력단 | Mfg-e8의 활성 제어를 통한 전능성 줄기세포의 선택적 세포사멸 유도 |
| WO2024012420A1 (zh) * | 2022-07-11 | 2024-01-18 | 士泽生物医药（苏州）有限公司 | 一种表达faslg的通用型细胞及其制备方法 |
| WO2024091959A1 (en) * | 2022-10-24 | 2024-05-02 | The Regents Of The University Of California | Drug resistant immune cells |
| CN116785312B (zh) * | 2023-06-21 | 2023-11-14 | 天津医科大学眼科医院 | miR-15a-5p在治疗眼底疾病中的应用 |
| CN119055769B (zh) * | 2023-08-17 | 2025-09-05 | 南方医科大学南方医院 | 抗血管生成药物在提高软组织移植物保留率中的应用 |
| WO2025064604A2 (en) * | 2023-09-19 | 2025-03-27 | Musc Foundation For Research Development | Combination engineered cell therapy |
| WO2025106557A1 (en) * | 2023-11-13 | 2025-05-22 | Bluerock Therapeutics Lp | Genetically modified cells for enhanced immune evasion in allogeneic cellular therapies |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002072798A1 (en) * | 2001-03-13 | 2002-09-19 | Johns Hopkins University School Of Medicine | Fas ligand-expressing hematopoietic cells for transplantation |
| EP1879448A2 (en) * | 2005-02-25 | 2008-01-23 | University of Chicago | Compositions and methods related to serpin spi6 |
| NZ597304A (en) * | 2005-10-13 | 2013-06-28 | Anthrogenesis Corp | Immunomodulation using placental stem cells |
| EP2300023A2 (en) | 2008-05-16 | 2011-03-30 | Genelux Corporation | Microorganisms for preventing and treating neoplasms accompanying cellular therapy |
| EP2547328B1 (en) * | 2010-02-11 | 2017-06-07 | Ecole Polytechnique Fédérale de Lausanne (EPFL) | Ccr7 ligand delivery and co-delivery in immunotherapy |
| TWI677507B (zh) * | 2012-06-22 | 2019-11-21 | 達特茅斯學院基金會 | 新穎之ｖｉｓｔａ－ｉｇ構築體及ｖｉｓｔａ－ｉｇ用於治療自體免疫、過敏及發炎病症之用途 |
| JP6297559B2 (ja) * | 2012-07-31 | 2018-03-20 | バジル・エム・ハンタッシュＢａｓｉｌ Ｍ． ＨＡＮＴＡＳＨ | Ｈｌａｇ改変された細胞および方法 |
| EP3021942A4 (en) * | 2013-07-19 | 2017-04-19 | The Regents of The University of California | Milk fat globule epidermal growth factor 8 regulates fatty acid uptake |
| SG10202006338UA (en) | 2014-06-18 | 2020-08-28 | Albert Einstein College Medicine Inc | Syntac polypeptides and uses thereof |
| WO2016081924A1 (en) * | 2014-11-20 | 2016-05-26 | Duke University | Compositions, systems and methods for cell therapy |
| ES2969389T3 (es) * | 2014-12-05 | 2024-05-17 | Regeneron Pharma | Animales no humanos que tienen un gen del grupo de diferenciación 47 humanizado |
| HUE055500T2 (hu) * | 2015-03-09 | 2021-11-29 | Sinai Health Sys | Eszközök és módszerek a sejtdivíciós loci használatára a sejtek szaporodásának szabályozására |
| EP3274715A4 (en) * | 2015-03-27 | 2018-10-10 | University of Southern California | Hla-g as a novel target for car t-cell immunotherapy |
| HK1254190A1 (zh) | 2015-05-08 | 2019-07-12 | President And Fellows Of Harvard College | 通用供体干细胞和相关方法 |
| US11207393B2 (en) * | 2015-10-16 | 2021-12-28 | President And Fellows Of Harvard College | Regulatory T cell PD-1 modulation for regulating T cell effector immune responses |
| MX2019008413A (es) | 2017-01-13 | 2019-09-13 | Univ California | Celulas pluripotentes inmunodiseñadas. |
| EP4017508A1 (en) | 2019-08-23 | 2022-06-29 | Sana Biotechnology, Inc. | Cd24 expressing cells and uses thereof |
-
2018
- 2018-06-12 IL IL270835A patent/IL270835B2/en unknown
- 2018-06-12 CN CN202510144417.3A patent/CN120041380A/zh active Pending
- 2018-06-12 EP EP18818206.7A patent/EP3638258A4/en active Pending
- 2018-06-12 WO PCT/CA2018/050706 patent/WO2018227286A1/en not_active Ceased
- 2018-06-12 KR KR1020247039926A patent/KR20250005439A/ko active Pending
- 2018-06-12 KR KR1020207000550A patent/KR102738427B1/ko active Active
- 2018-06-12 AU AU2018285972A patent/AU2018285972B2/en active Active
- 2018-06-12 GB GB1917408.5A patent/GB2588249B/en active Active
- 2018-06-12 CA CA3064297A patent/CA3064297A1/en active Pending
- 2018-06-12 IL IL314638A patent/IL314638A/en unknown
- 2018-06-12 CN CN201880038734.5A patent/CN110869494B/zh active Active
- 2018-06-12 US US16/621,490 patent/US20210161971A1/en not_active Abandoned
- 2018-06-12 JP JP2020518110A patent/JP7391016B2/ja active Active
-
2023
- 2023-02-27 US US18/175,409 patent/US12178835B2/en active Active
- 2023-06-15 AU AU2023203759A patent/AU2023203759B2/en active Active
- 2023-11-21 JP JP2023197046A patent/JP7724834B2/ja active Active
-
2024
- 2024-11-15 US US18/949,799 patent/US20250144154A1/en active Pending
-
2025
- 2025-08-05 JP JP2025130460A patent/JP2025163187A/ja active Pending
- 2025-08-18 AU AU2025217410A patent/AU2025217410A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020523037A5 (enExample) | ||
| JP2024026125A5 (enExample) | ||
| GB2588249A (en) | Allograft tolerance without the need for systemic immune suppression | |
| EP3471743B1 (en) | Strategies to assess and/or produce cell populations with predictive engraftment potential | |
| AU2011377617B2 (en) | Improved gene therapy methods | |
| US20190184035A1 (en) | Bcl11a homing endonuclease variants, compositions, and methods of use | |
| RU2205029C2 (ru) | Генетически измененные клетки и их применение для профилактики или лечения заболеваний | |
| IL308706A (en) | Compositions and methods for the treatment of hemoglobinopathies | |
| JP2004519245A (ja) | 肝臓細胞の増殖方法、該方法により得られる肝臓細胞、およびその用途 | |
| JP6861438B2 (ja) | Ｅｔｓ転写因子を発現する改変内皮細胞 | |
| JP2006505266A (ja) | 幹細胞の増幅因子 | |
| Brenner | Gene marking | |
| Conget et al. | Identification of a discrete population of human bone marrow-derived mesenchymal cells exhibiting properties of uncommitted progenitors | |
| JP2004505620A (ja) | 動静脈特性の操作 | |
| JP7150233B2 (ja) | 多能性幹細胞を用いた自殺遺伝子脳腫瘍治療薬 | |
| EP1636336A2 (en) | Smooth muscle progenitor cells | |
| JP4834291B2 (ja) | Ｓｔａｔ３活性化幹細胞 | |
| Migliaccio et al. | In vivo expansion of purified hematopoietic stem cells transplanted in nonablated W/Wv mice | |
| JP2025506976A (ja) | 低免疫原性幹細胞、幹細胞から分化または由来した低免疫原性細胞およびこの製造方法 | |
| CN114514315B (zh) | 产自尿液细胞的内皮和平滑肌样组织及其相关用途 | |
| Staquicini et al. | Phage display technology for stem cell delivery and systemic therapy | |
| WO2001048150A1 (en) | Cells capable of differentiating into heart muscle cells | |
| Lanza et al. | Long-term bovine hematopoietic engraftment with clone-derived stem cells | |
| WO2001048149A1 (en) | Adult bone marrow-origin cell capable of differentiating into heart muscle cell | |
| Nordon et al. | Summary and Future Directions |